Stable Pools Move Biologics Off the Clone-First Path

By Rebecca Stone

GBI Biomanufacturing's SmartScale workflow links a stable cell pool (a mixed population carrying an integrated expression construct) to a shake-flask upstream process that reaches 7 liters, followed by downstream purification, drug substance (bulk biologic) manufacturing and fill-finish under good manufacturing practice (GMP) controls. The company presents this as an alternative route to clinical material for first-in-human studies.

The account comes from GBI's Jesse McCool, PhD, and centers on technology his company developed. It supplies no independent study citation, molecule names, batch counts, sample sizes, numerical comparability ranges, development timeline, cost saving or funding disclosure. Sponsors therefore have a workflow proposal and historical summary, not a measured comparison of time to first clinical supply.

Why move cloning off the critical path?

For decades, conventional biologics development has followed a fixed sequence: construct an expression system, transfect host cells, isolate single cells, screen hundreds or thousands of clones, select a lead, establish a cell bank, develop the process and manufacture clinical material. The model works, but it places cloning before the first clinical question.

For many first-in-human programs, commercial manufacturing is not the immediate goal. Teams need a modest quantity of well-characterized material, suitable controls and evidence that a candidate merits further investment. Moving cloning later changes the order of work, not the need to characterize what they make.

A stable pool differs from transient expression because the expression construct integrates into the host-cell genome. It remains a mixed population rather than one selected cell. Conventional random integration can produce differences in transgene copy number, insert integrity and integration site, which then affect growth, productivity, stability and product quality.

Single-cell cloning addresses that heterogeneity by searching the population for an individual clone with the desired traits. McCool instead points to GBI's Leap-In Transposase platform, which uses an enzyme-driven, cut-and-paste mechanism for DNA integration. The company says the controlled process can generate stable pools with a narrower distribution of cellular traits than random integration.

His formulation captures the operating distinction: “The pool does not become clonal. It becomes more predictable.” A more predictable population can serve as the manufacturing substrate while cloning proceeds in parallel or starts later.

What evidence must justify deferring a clone?

Deferred cloning does not mean deferred characterization. A pool headed for GMP manufacture needs a control strategy that covers:

• Cell identity, purity and testing for adventitious agents (unintended contaminants);
• Population-doubling limits and evidence that the population remains suitable throughout the intended manufacturing window.

The protein itself needs identity, purity, potency and other product-quality attributes appropriate for the intended clinical study. Those requirements apply regardless of whether a clone or stable pool produced the material.

GBI cites published experience with transposon-generated stable pools as proof of concept, including GMP production at substantial scale. It says later clone-derived processes showed comparable process performance and product-quality profiles, but the source does not name those studies or report their underlying values.

• Process comparisons tracked viable cell concentration, viability, antibody titer (concentration) and cell-specific productivity (product per cell over time).
• Product comparisons covered purity, charge variants (forms with altered electrical charge) and glycosylation (sugar modification), with results within comparable ranges.

Those findings do not establish identity between a pool and its derivative clone on every assay. Historical performance also cannot replace molecule-specific assessment. The defensible claim is narrower: developers can characterize and manage the relationship between pool-derived and clone-derived material.

Can small-scale manufacturing fit first clinical studies?

Early clinical studies often need modest amounts, especially for potent antibodies and other protein therapeutics. Sponsors frequently use infrastructure built for much larger requirements. A small-scale, closed upstream process can match capacity to the actual study and limit material produced before efficacy is known.

SmartScale links stable-pool development to OptimumGrowth shake flasks, moving from seed culture through a 7-liter production stage. It then joins upstream processing to downstream purification, drug substance and fill-finish. GBI's stated rule is to use the smallest robust GMP process that can supply the clinical program's required quantity.

Starting small must not trap a successful product. The plan should allow transfer to larger single-use bioreactors and to fed-batch or perfusion processing if clinical demand rises. Scale choice therefore remains tied to the study's material requirement and possible later demand.

How should sponsors sequence development risk?

Historically, developers have tried to resolve later-stage technical and clinical risks before giving a first dose. That can make sense when the probability of technical or clinical success is high. For a novel therapy, however, the sequence can consume substantial time and capital before anyone knows whether the drug works in patients.

A phase-appropriate chemistry, manufacturing and controls (CMC) strategy does not remove development work. It sequences the work according to the evidence available at each stage.

The proposed sequence starts with a controlled stable pool, population characterization, a small GMP batch and the CMC package needed for initial clinical investigation. Developers can run single-cell cloning in parallel or wait for clinical evidence before committing to a derivative clone.

If the clinical signal supports further investment, the program can select and bank a derivative clone, expand process characterization and demonstrate comparability between pool- and clone-derived material. That makes comparability a defined development activity rather than an assumption carried from the start.

Not every biologic fits. Difficult product-quality profiles, unstable expression, unusual safety considerations or large material needs at the outset can favor conventional clone-first development. The relevant choice depends on molecule risk and study scale, not a universal preference for one workflow.

McCool frames the test for sponsors under capital pressure and pressure to reach meaningful milestones as a direct operational question: “Can stable pools move biologics to first-in-human studies faster?” The next evidence for portfolio decisions is molecule-specific batch data showing that small-scale pool material meets study needs while clone selection remains a viable parallel workstream.